FReP Cell Reprogramming via Fibromodulin to Prevent Teratomas
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for culturing human embryonic stem cells face challenges such as reliance on animal products, risk of genome instability, and teratoma formation during pluripotency reprogramming, which complicates their therapeutic application.
Innovation Solution
A cell culture medium comprising fibromodulin (FMOD) is used to reprogram cells into FMOD reprogrammed (FReP) cells that express NANOG and do not form teratomas, eliminating the need for genome-integrated transcription factors and animal-derived components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genome-integrated transcription factors are used for reprogramming, then pluripotency is achieved, but genome instability and teratoma formation occur
Solution Approach 1:
The invention extracts and eliminates the harmful genome-integrated transcription factors from the reprogramming process. Instead of using integrated factors, the patent employs non-integrated alternatives such as protein transduction, mRNA transfection, or epigenetic modifiers that achieve pluripotency induction without genomic integration, thereby preventing genome instability and teratoma formation while maintaining reliable pluripotency induction
Solution Approach 2:
The invention introduces intermediary substances such as small molecules, proteins, or epigenetic modifiers that mediate the reprogramming process without requiring genomic integration. These intermediaries temporarily induce pluripotency markers and maintain pluripotent state without becoming part of the genome, thus achieving reliable reprogramming while avoiding the harmful effects of integrated factors
2Productivity
If animal products are used in culture medium, then cell growth is supported, but batch variability and contamination risk increase
Solution Approach 1:
The invention replaces expensive, variable animal-derived components with defined, synthetic alternatives that can be precisely controlled. The use of chemically defined media components, recombinant growth factors, and synthetic extracellular matrix substitutes eliminates batch-to-batch variability associated with animal products while maintaining support for cell growth and pluripotency
Solution Approach 2:
The invention changes the chemical composition parameters of the culture medium by replacing animal-derived components with defined synthetic alternatives. This includes using specific concentrations of amino acids, vitamins, growth factors, and buffer systems that provide consistent, reproducible cell growth support without the variability inherent in animal products
3Adaptability or versatility
If human ES cells are differentiated in undirected fashion, then heterogeneous cell population is obtained, but specific therapeutic cell types cannot be produced
Solution Approach 1:
The invention applies local quality control to differentiation by using specific growth factors, signaling molecules, and culture conditions that direct differentiation toward particular lineages. By locally optimizing the microenvironment with lineage-specific cues such as retinoic acid for neural differentiation or BMPs for mesodermal differentiation, the patent achieves both versatile differentiation capacity and precise control over the specific cell types produced
Solution Approach 2:
The invention employs preliminary action by pre-determining the differentiation pathway through staged culture protocols. Cells are first directed toward a specific lineage commitment using preliminary differentiation cues, then further specialized through subsequent culture conditions, ensuring both the versatility to produce multiple cell types and the precision to generate specific therapeutic cell populations
Data Source
AI summary
The present invention provides a method of forming a fibromodulin (FMOD) reprogrammed (FReP) cell. The method comprises steps of treating a human cell with a cell culture medium comprising fibromodulin (FMOD) for a period ranging from a day to a month, and changing the cell culture medium regularly until a FMOD reprogrammed (FreP) cell forms; wherein the FreP cell expresses NANOG and does not form teratoma, and wherein the human cell is a fibroblastic cell.